-$0.32 EPS Expected for Immunomedics, Inc. (IMMU) This Quarter

Equities research analysts forecast that Immunomedics, Inc. (NASDAQ:IMMU) will announce earnings per share (EPS) of ($0.32) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Immunomedics’ earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.30). Immunomedics posted earnings of ($0.19) per share in the same quarter last year, which would suggest a negative year over year growth rate of 68.4%. The firm is expected to report its next earnings report on Thursday, February 14th.

According to Zacks, analysts expect that Immunomedics will report full-year earnings of ($1.20) per share for the current year, with EPS estimates ranging from ($1.33) to ($1.00). For the next financial year, analysts forecast that the firm will report earnings of ($0.88) per share, with EPS estimates ranging from ($1.32) to ($0.68). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Immunomedics.

Immunomedics (NASDAQ:IMMU) last issued its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). Immunomedics had a negative return on equity of 85.57% and a negative net margin of 12,701.21%. During the same quarter in the prior year, the business posted ($0.97) EPS.

A number of equities analysts have weighed in on the stock. BidaskClub upgraded shares of Immunomedics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. Zacks Investment Research upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 29th. Morgan Stanley assumed coverage on shares of Immunomedics in a report on Monday, November 5th. They issued an “overweight” rating and a $38.00 price target on the stock. Jefferies Financial Group assumed coverage on shares of Immunomedics in a report on Thursday, November 8th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, TheStreet downgraded shares of Immunomedics from a “c-” rating to a “d+” rating in a report on Tuesday, September 11th. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $38.43.

Shares of NASDAQ:IMMU opened at $18.70 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 13.45 and a quick ratio of 13.45. The stock has a market cap of $3.55 billion, a price-to-earnings ratio of -18.16 and a beta of 1.93. Immunomedics has a twelve month low of $8.68 and a twelve month high of $27.33.

Several institutional investors have recently made changes to their positions in IMMU. Legal & General Group Plc lifted its holdings in shares of Immunomedics by 100.7% in the first quarter. Legal & General Group Plc now owns 52,358 shares of the biopharmaceutical company’s stock worth $765,000 after buying an additional 26,270 shares in the last quarter. Amalgamated Bank lifted its holdings in shares of Immunomedics by 47.4% in the second quarter. Amalgamated Bank now owns 19,954 shares of the biopharmaceutical company’s stock worth $472,000 after buying an additional 6,415 shares in the last quarter. Shaker Investments LLC OH raised its stake in Immunomedics by 218.2% in the second quarter. Shaker Investments LLC OH now owns 84,015 shares of the biopharmaceutical company’s stock valued at $1,989,000 after purchasing an additional 57,615 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Immunomedics by 1.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 554,914 shares of the biopharmaceutical company’s stock valued at $13,135,000 after purchasing an additional 7,694 shares in the last quarter. Finally, TD Asset Management Inc. raised its stake in Immunomedics by 25.9% in the second quarter. TD Asset Management Inc. now owns 215,088 shares of the biopharmaceutical company’s stock valued at $5,091,000 after purchasing an additional 44,288 shares in the last quarter. 75.96% of the stock is currently owned by hedge funds and other institutional investors.

Immunomedics Company Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Recommended Story: Capital gains and your 401(k) or IRA

Get a free copy of the Zacks research report on Immunomedics (IMMU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply